Establishment of predictive marker for epigenetic drugs in hematological malignancies
Project/Area Number |
23590687
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | Kitasato University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
SATOH Takashi 北里大学, 医療衛生学部, 講師 (90407114)
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | バイオマーカー / 分化 / PU.1 / メタロチオネイン / 白血病 / エピジェネティック |
Outline of Final Research Achievements |
First, we examined the effect of DNA methylation inhibitor on various PU.1 transgenic leukemia cell lines. As a result, we found a positive correlations for PU.1 expression and DNA methylation inhibitor effect, which induced differentiation and finally elimination of leukemia cells. Next, we assessed whether this effect is correlated with metallothionein (MT) expression, which we recently found an novel suppressive target gene of PU.1. To this aim, we generated MT over-expressed acute promyelocytic leukemia NB4 cell line (NB4MTOEcells) and examined the effect of all-trans retinoic acid (ATRA), which is a potent differentiation inducer for NB4 cells. We revealed that the effect of ATRA is inhibited in NB4MTOE cells. This is quite consistent with our prediction, because PU.1 is a suppressive regulator of MT. Collectively, these results suggest that expressions of PU.1 and MT may serve as useful biomarkers to predict the efficacy of epigenetic drugs which have differentiation effects.
|
Report
(5 results)
Research Products
(37 results)
-
-
-
-
-
-
-
[Journal Article] Fcγ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia.2013
Author(s)
Satoh T1, Miyazaki K, Shimohira A, Amano N, Okazaki Y, Nishimoto T, Akahoshi T, Munekata S, Kanoh Y, Ikeda Y, Higashihara M, Takahashi S, Kuwana M.
-
Journal Title
Blood
Volume: Sep 12;122
Issue: 11
Pages: 1991-2
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Detection of Anti-Thrombopoietin antibodies in patients with immune thrombocytopenia2014
Author(s)
Satoh T, Miyazaki T, Osawa E, Modegi N, Kita A, Kurihara S, Kawasaki Y, Shimada N, Nagane K, Higashihara M, Takahashi S
Organizer
American Society of Hematology Meeting
Place of Presentation
San Francisco Mascone Convention Center, San Francisco, USA
Year and Date
2014-12-08
Related Report
-
-
[Presentation] Analysis of anti-thrombopoietin antibody in patients with immune thrombocytopenia2014
Author(s)
Satoh T, Miyazaki K, Shimada N, Nagane K, Kita A, Kurihara S, Kawasaki Y, Kodaira Y, Osawa E, Modegi N, Higashihara M, Takahashi S
Organizer
日本血液学会
Place of Presentation
大阪国際会議場(大阪府大阪市)
Year and Date
2014-11-02
Related Report
-
-
[Presentation] Detection of anti-thrombopoietin autoantibody among immune thrombocytopenic patients2014
Author(s)
Miyazaki T, Satoh T, Osawa E, Modegi N, Kita A, Kurihara S, Kawasaki Y, Shimada N, Nagane K, Higashihara M, Takahashi S
Organizer
19th Congress of European Hematology Association Meeting
Place of Presentation
Milano Congressi, Milan, Italy
Year and Date
2014-06-13
Related Report
-
-
-
-
-
-
-
-
[Presentation] Analysis of Fcg receptor 2A, 2B and 3A polymorphisms in adults with immune thrombocytopenia
Author(s)
Satoh T, Shimohira A, Amano N, Okazaki Y, Nishimoto T, Akahoshi T, Munekata S, Knoh Y, Okada J, Ikeda Y, Miyazaki K, Higashihara M, Kuwana M and Takahashi S
Organizer
日本血液学会
Place of Presentation
京都
Related Report
-
-
-
-
-
-